Skip to main content

Table 1 Association between patient characteristics and treatment group

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic Immunosuppressant
N = 141
No immunosuppressant
N = 41
P value
Age in years, mean (SD) 60 (15) 58 (19) 0.371
Male sex, n (%) 94 (66.7) 25 (61.0) 0.576
White race, n (%) 135 (95.7) 32 (78.0) 0.001
Comorbidities present, n (%) 79 (56.0) 28 (68.3) 0.207
Smoking, n (%) 74 (52.5) 22 (53.7) 1.000
NSAID, n (%) 76 (53.9) 20 (48.8) 0.597
Malignancy type, n (%)    0.016
 Melanoma 62 (44.0) 15 (36.6)  
 Solid 74 (52.5) 19 (46.3)  
 Hematological 5 (3.5) 7 (17.1)  
Cancer stagea, n (%)    1.000
 III 13 (9.6) 3 (8.8)  
 IV 122 (90.4) 31 (91.2)  
Checkpoint inhibitor type, n (%)    0.051
 CTLA-4 59 (41.8) 12 (29.3)  
 PD-1/L-1 45 (31.9) 22 (53.7)  
 Combinationb 37 (26.2) 7 (17.1)  
Diarrhea grade    <  0.001
 1 4 (2.8) 20 (48.8)  
 2 43 (30.5) 17 (41.5)  
 3–4 94 (66.7) 4 (9.8)  
Colitis grade    <  0.001
 1 23 (16.3) 14 (34.1)  
 2 59 (41.8) 27 (65.9)  
 3–4 59 (41.8) 0 (0.0)  
Endoscopic evaluation    0.223
 Flexible sigmoidoscopy 33 (23.4) 14 (34.1)  
 Colonoscopy 108 (76.6) 27 (65.9)  
Distribution of colitis    <  0.001
 Terminal ileum involved 10 (7.1) 1 (2.4)  
 Right colon only 4 (2.8) 1 (2.4)  
 Left colon only 48 (34.0) 9 (22.0)  
 Entire colon 39 (27.7) 3 (7.3)  
 Normal 40 (28.4) 27 (65.9)  
IBD like endoscopic patternc    0.229
 Crohn’s colitis 32 (31.7) 7 (50.0)  
 Ulcerative colitis 69 (68.3) 7 (50.0)  
  1. Abbreviation: NSAID, non-steroidal antiinflammatory drugs, CTLA-4 cytotoxic T-lymphocyte antigen-4, PD-1/L-1 programmed cell death receptor-1 and ligand 1, SD standard deviation
  2. a American Joint Committee on Cancer (AJCC) Cancer Staging System, 13 patients are missing
  3. b Combination: ipilimumab + nivolumab
  4. c Only 115 patients were included for the IBD like endoscopic pattern evaluation